Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda

Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an “orexin” market that analysts see as a multibillion-dollar opportunity.